Patent Application
20240226171
The present invention relates to a composition for promoting neurogenesis, including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate that are produced using a novel production method, and a method for promoting neurogenesis.
Treatments using stem cells, particularly mesenchymal stem cells (MSC), and positive clinical results have been reported for various diseases. However, stem cell therapy has a risk of cell-related side effects such as vascular occlusion, tumor formation, and coagulation disorders, and efficacy verification through clinical trials is still required. It is known that a paracrine effect of stem cells induces the promotion of the regeneration and vascular regeneration of surrounding skin cells, and in particular, extracellular vesicles (EV) are known as a major efficacious factor in the paracrine effect.
The extracellular vesicles are classified into exosomes and microvesicles depending on a size, and the exosomes have a diameter of 30 to 150 nm, and the microvesicles have a size of 100 to 1,000 nm. The extracellular vesicles are parts of the cell membrane that have been separated into the blood, and are known to mediate intercellular communication by containing both protein and nuclear components. Using extracellular vesicles instead of stem cells not only increases safety by minimizing the side effects by using stem cells, but also is advantageous in terms of biodistribution and production process.
Brain neuroplasticity is a phenomenon in which neural pathways are structurally and functionally changed and reorganized. In not only brain injuries such as cerebral infarction and head trauma, but also dementia and many degenerative neurological diseases, damage or reduction of neural pathways causes symptoms. To date, there is no possible treatment or method to restore brain neural pathways, and the treatment or method has not been applied clinically to patients with brain diseases such as cerebral infarction and dementia. Currently, physical therapy, behavioral therapy, and the like have been applied to these patients, but the treatment effect thereof is limited. Therefore, it is expected that improvement of brain neuroplasticity through enhancement of neurogenesis and neural circuit restoration may exhibit a therapeutic effect on most brain diseases.
However, mass production, obtaining method, and the like for using extracellular vesicles derived from stem cells have not yet been established, and much research has been not conducted on methods to further enhance the efficacy of extracellular vesicles while maintaining the characteristics of stem cell-derived extracellular vesicles. In addition, particularly, extracellular vesicles capable of improving brain neuroplasticity have not been widely studied.
Accordingly, there is a need for extracellular vesicles with improved efficacy and novel therapeutic agents using the same.
Therefore, the present inventors studied a method capable of shortening a culture time while enabling mass production, in order to produce three-dimensional spheroid-type cell aggregate or extracellular vesicles derived therefrom. As a result, the present inventors confirmed that extracellular vesicles capable of improving neuroplasticity by promoting neurogenesis were produced by producing three-dimensional spheroid-type cell aggregate (3D-static-spheroids) through static culture using a microwell and producing extracellular vesicles using the same, and then completed the present invention.
Accordingly, an object of the present invention is to prepare extracellular vesicles derived from three-dimensional spheroid-type cell aggregate with improved neurogenesis ability and to provide a composition for preventing, improving or treating neurological diseases and damage including the same.
An aspect of the present invention provides a pharmaceutical composition for preventing or treating neurological diseases and damage including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm; and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
Another aspect of the present invention provides a food composition for preventing or improving neurological diseases and damage including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
Yet another aspect of the present invention provides an in vitro composition for promoting neurogenesis including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
Yet another aspect of the present invention provides a method for producing a composition for promoting neurogenesis including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate, including (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm; and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
Yet another aspect of the present invention provides a method for preventing or treating neurological diseases and damage including: (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: (b) preparing extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate by isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate: and (c) treating the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate prepared in step (b) to a subject in need thereof.
According to the present invention, extracellular vesicles prepared by a novel preparation method can improve neuroplasticity by inducing neurogenesis, neuronal differentiation or neural circuit restoration, and thus can be effectively used in the treatment of various diseases requiring neurogenesis.
The present invention provides a pharmaceutical composition for preventing or treating neurological diseases and damage including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm; and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
In the present invention, the cells may be used without limitation as long as the cells are cells capable of isolating extracellular vesicles, and may be cells isolated from a natural organism. In addition, the cells may be derived from any type of animal or plant, including humans and non-human mammals, and may be various types of immune cells, tumor cells, and stem cells, and preferably, the stem cells may be mesenchymal stem cells, pluripotent stem cells, induced pluripotent stem cells, or embryonic stem cells.
In the present invention, the 3D culture means culturing in a three-dimensional arrangement in vitro, and unlike 2D culture, the cell growth in the 3D culture may grow cells in all directions in vitro and may be more similar to an in vivo cell environment.
In the present invention, the 3D culture in step (a) may be performed by any 3D cell culture technique known in the art to which the present invention pertains, and may be a cell culture using, for example, microwell array culture, porous microsphere culture, hanging drop culture, low attachment plate culture, membrane-based cell-detachment culture, thermal lifting culture, centrifugation culture, semisolid medium culture, and the like. Preferably, the 3D culture may be dynamic culture or static culture, more preferably static culture. In the present invention, when the 3D culture of step (a) is static culture, it makes it easier to culture without requiring devices necessary for shaking culture, and mass-culture is enabled in the Good Manufacturing Practices (GMP) manufacturing place.
In the present invention, the 3D culture in step (a) may be performed for 1 to 10 days, preferably 2 to 4 days. In the present invention, when the culture in step (a) is performed for 2 to 4 days, the viability of cells present in the three-dimensional spheroidal cell aggregate is maintained at a high level, and compared to a conventional process of producing three-dimensional spheroid-type cell aggregate, the culture time is relatively short, so that it is possible to rapidly produce three-dimensional spheroid-type cell aggregate and extracellular vesicles derived therefrom.
In the present invention, the 3D culture in step (a) may be performed by dispensing mesenchymal stem cells in a microwell at a density of 100 to 1000 cells/well, preferably a density of 100 to 600 cells/well, more preferably a density of 100 to 500 cells/well.
In the present invention, in the isolating of the extracellular vesicles in step (b), a sample containing cells or a cell aggregate may be prepared by using a method selected from the group consisting of extrusion, sonication, cell lysis, homogenization, freeze-thawing, electroporation, chemical treatment, mechanical degradation, and treatment of physical stimuli externally applied to cells, preferably isolated by a tangential flow filtration (TFF) method, but is not limited thereto.
In the present invention, microRNA is named by attaching “mir” in the front and adding “-” and a number at the end. At this time, the numbers often indicate the order to be named, and for example, mir-123 was named before mir-156 and is expected to have been identified earlier. “mir-” indicates pre-microRNA, and capitalized “miR” refers to mature microRNA. Except for one or two sequences, microRNAs with almost identical sequences are named by adding small letters. For example, miR-121a and miR-121b were generated from respective precursors mir-121a and mir-121b, and their sequences are very similar. Mature microRNAs are identical, but pre-microRNAs located at different sites on a genome are named by adding “-” and a number. For example, the pre-microRNAs mir-121-1 and mir-121-2 become the same mature microRNA (miR-121), but are located at different sites on the genome. Species-specific names of microRNAs are indicated in the front. For example, hsa-miR-123 is Homo sapiens microRNA, and oar-miR-123 is Ovis aries microRNA. ‘v’ means viral (miRNA encoded by a viral genome) and ‘d’ means Drosophila microRNA. When two mature microRNAs are derived from different arms (3′ arm or 5′ arm) of the same pre-microRNA, the mature microRNAs are named by adding ‘-3p’ or ‘-5p’ to the end. miR-142-3p is derived from the 3′ arm, and miR-142-5p is derived from the 5′ arm. The nomenclature of MicroRNA generally follows the above criteria, but there are exceptions.
In the present invention, the extracellular vesicles may highly express clinically significant substances compared to known extracellular vesicles, and the clinically significant substances may be substances exhibiting a neurogenesis effect. For example, preferably, the extracellular vesicles of the present invention may highly express at least one selected from the group consisting of neurogenesis-related miR-27a, miR-132, miR-146a, and miR-146b compared to extracellular vesicles derived from a spheroidal cell aggregate obtained by 3D dynamic culture of mesenchymal stem cells and extracellular vesicles derived from 2D-cultured mesenchymal stem cells, and may highly express at least one selected from the group consisting of a vascular endothelial growth factor (VEGF), a brain-derived neurotrophic factor (BDNF), a brain-derived neurotrophic factor (FGF) and a brain-derived neurotrophic factor (NGF) compared to extracellular vesicles derived from a spheroidal cell aggregate obtained by 3D dynamic culture of mesenchymal stem cells and extracellular vesicles derived from 2D-cultured mesenchymal stem cells. More preferably, the extracellular vesicles of the present invention may highly express all neurogenesis-related miR-27a, miR-132, miR-146a, and miR-146b, VEGF, BDNF, FGF and NGF compared to extracellular vesicles derived from a spheroidal cell aggregate obtained by 3D dynamic culture of mesenchymal stem cells and extracellular vesicles derived from 2D-cultured mesenchymal stem cells.
In addition, the extracellular vesicles may be incorporated and internalized into cells upon treatment with cells, and when incorporated and internalized into cells, a clinically significant substance highly expressed in the extracellular vesicles may be effectively delivered to cells to be highly expressed in cells.
In the present invention, the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate that exhibit a neurogenesis-promoting effect may be used interchangeably with “3D-static-spheroid-EVs”. In addition, in comparison, the extracellular vesicles derived from the 3D dynamically cultured spheroidal cell aggregate may be used interchangeably with “3D-dynamic-PEG-spheroid-EVs”.
In the present invention, the “extracellular vesicles derived from the spheroidal cell aggregates obtained by 3D dynamic culture of mesenchymal stem cells” are any extracellular vesicles isolated from spheroidal cell aggregates obtained by 3D dynamic culture of mesenchymal stem cells without limitation, preferably extracellular vesicles disclosed in Registration Patent (application No. 10-2016-0053026, method for producing stem cell-derived extracellular vesicles).
In the present invention, the “extracellular vesicles derived from 2D-cultured mesenchymal stem cells” may be any extracellular vesicles obtained by culturing stem cells according to a conventional 2D culture method and isolated from the stem cells by a conventional method of isolating extracellular vesicles without limitation. In an embodiment of the present invention, the conventional 2D culture method was performed by a method of washing stem cells cultured for 3 days in a cell stack with PBS, replacing the medium with a serum-free medium, and further culturing the cells for 2 days.
In the present invention, the three-dimensional spheroid-type cell aggregate may have an average diameter of 74.43±7.756 μm, preferably a size range of 55 to 95.0 μm. As a result of measuring the size distribution of 155 three-dimensional spheroid-type cell aggregate, the average diameter may be 74.43 μm and the coefficient of variance (CV) may be 9.59%. The three-dimensional spheroidal cell aggregate of the present invention may have a higher kurtosis in size distribution than the “spheroidal cell aggregate obtained by 3D dynamic culture of mesenchymal stem cells”. Therefore, the size of the three-dimensional spheroid-type cell aggregate is smaller than that of the “spheroidal cell aggregate obtained by 3D dynamic culture of mesenchymal stem cells”, and may have a relatively uniform size distribution.
In the present invention, the microwell may be coated with any one selected from the group consisting of TMSPMA (3-(Trimetoxysily) propylmethacrylate), HEA (Hydroxyethyl acrylate), GMA (Glycidyl methacrylate), EGDMA (diethyleneglycol dimethacrylate), THFA (Tetrahydrofurfuryl acrylate), HMAA (Hydroxymethul acrylamide), PEA (Phenyl epoxyacrylate), HOFHA (6-Hydroxy-2,2,3,3,4,4,5,5-octafluoro), EOPT (Polyethoxylated(4)pentaery thritoltetraacrylate), HPA (Hydroxypropyl acrylate), BMA (Buthylmethacrlate), PETIA (Pentaerythritol triacrylate), HDDA (Hexan diol diacrylate), EGPEA (Ethyleneglycol phenyletheracrylate), BM (Benzylmethacrylate), HPPA (Hydroxyphenoxypropyl acrylate), BHPEA (2-(4-Benzoyl-3-hydroxyphenoxy)ethylacrylate), HEMA (Hydroxyethyl methacrylate), HPMA (N-(2-Hydroxypropyl) methacrylamide) and MPC (2-Methacryloyloxyethyl Phosphorylcholine Polymer), and preferably, coated with MPC (2-Methacryloyloxyethyl Phosphorylcholine Polymer), but is not limited thereto.
The microwell of the present invention may have a diameter of 200 to 800 μm, preferably 300 to 800 μm, and more preferably 400 to 800 μm.
In addition, the microwell may be a microwell with a flat structure without depth, or in the case of a microwell with a depth, the microwell may have a structure of 100 to 1000 μm, preferably 100 to 900 μm, and more preferably 200 to 900 μm.
The mesenchymal stem cells cultured by the structure may maintain a high survival rate even after the culture time has elapsed. Preferably, the production yield of cell aggregates may be increased by manufacturing a microarray including 1,000 to 100,000 microwells.
When the extracellular vesicles are produced by the “method for producing the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate” of the present invention, in addition to the manufacturing advantages of static culture, extracellular vesicles with improved clinical applicability, especially neurogenesis ability such as neurogenesis, neuronal differentiation, and neural circuit restoration may be mass-produced quickly and efficiently. In particular, existing methods for producing extracellular vesicles, such as a method for producing “extracellular vesicles derived from spheroidal cell aggregates obtained by 3D dynamic-culturing of mesenchymal stem cells in a 3 dimension” or a method of producing “extracellular vesicles derived from mesenchymal stem cells 2D cultured”, are unsuitable for GMP. However, the method for producing extracellular vesicles of the present invention has a characteristic of being suitable for GMP application to be particularly suitable for producing a pharmaceutical composition for preventing or treating neurological diseases and damage.
In the present invention, the neuroplasticity refers to a phenomenon in which neural pathways are structurally and functionally changed and reorganized.
According to the present invention, neuroregeneration, neurogenesis induction, and neuronal differentiation induction may be effectively achieved by treating extracellular vesicles derived from three-dimensional spheroid-type cell aggregate, thereby improving neuroplasticity.
Accordingly, the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate of the present invention can be applied to various neurological diseases, nerve damage, and conditions requiring nerve regeneration. The types of diseases to which the extracellular vesicles of the present invention may be applied are not limited thereto, but may be at least one disease or damage selected from the group consisting of spinal cord injury, Parkinson's disease, stroke, amyotrophic spinal lateral sclerosis, motor nerve damage, peripheral nerve damage due to trauma, nerve damage due to ischemic brain damage, neonatal hypoxic brain injury, cerebral palsy, epilepsy, intractable epilepsy, Alzheimer's disease, congenital metabolic nervous system disease, and traumatic brain injury. In addition, in particular, the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate of the present invention may be used for inducing neurogenesis, neuronal differentiation, or neural circuit restoration.
In the present invention, in order to determine whether the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate may induce neural circuit restoration, the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate were administered to an animal model, and diffusion-tensor image (MRI DTI) analysis was performed. As a result, it was confirmed that the neural circuit was regenerated and the increase in nerve fibers was promoted.
The pharmaceutical composition of the present invention may further include suitable carriers, excipients, and diluents which are commonly used in the preparation of pharmaceutical composition in addition to the active ingredient. The pharmaceutical composition of the present invention may further include other pharmaceutically active ingredients or active mixtures.
The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to conventional methods, respectively. The carrier, the excipient, and the diluent that may be included in the composition may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. When the pharmaceutical composition is formulated, the formulation may be prepared by using diluents or excipients, such as a filler, an extender, a binder, a wetting agent, a disintegrating agent, and a surfactant, which are generally used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid formulations may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like. Further, lubricants such as magnesium stearate and talc are used in addition to simple excipients.
Liquid formulations for oral administration may correspond to suspensions, oral liquids, emulsions, syrups, and the like, and may include various excipients, for example, a wetting agent, a sweetener, an aromatic agent, a preservative, and the like, in addition to water and liquid paraffin which are commonly used as simple diluents. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, and suppositories. As the non-aqueous solution and the suspension, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like may be used. As a base compound of the suppository, witepsol, macrogol, tween 61, cacao butter, laurinum, glycerogelatin, and the like may be used.
A preferable dose of the pharmaceutical composition of the present invention varies according to the condition and weight of a patient, the degree of a disease, a drug form, and the route and period of administration, but may be properly selected by those skilled in the art. The administration may be performed once a day or several times a day. The dose does not limit the scope of the present invention in any aspect.
The pharmaceutical composition of the present invention may be administered to mammals such as mice, rats, livestock, and humans through various routes. All methods of administration may be expected, and for example, the pharmaceutical composition may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
The definitions of terms for the excipients, binders, disintegrants, lubricants, flavor enhancers, flavoring agents, and the like of the present invention are described in literature known in the art and include those with the same or similar functions.
Further, the present invention provides a method for preventing or treating neurological diseases and damage including (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: (b) preparing extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate by isolating cells and vesicles from the three-dimensional spheroid-type cell aggregate: and (c) treating the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate prepared in step (b) to a subject in need thereof.
The subject is preferably mammals, including humans, and patients in need of treatment of neurological diseases include all patients being treated for nerve damage or neurological diseases, patients who have previously received treatment of nerve damage or neurological diseases, and patients in need of treatment for nerve damage or neurological diseases, and may also include patients who have undergone surgical procedures for treatment of nerve damage or neurological diseases.
In addition, the present invention may be treated in combination with existing drugs or treatment methods for treatment of nerve damage or neurological diseases. When the present invention is treated in combination, the present invention may be treated simultaneously or sequentially with other drugs or treatment methods for treatment of nerve damage or neurological diseases.
Further, the present invention provides a food composition for preventing or improving neurological diseases and damage including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
The food composition may be cited in the same manner as the description of the pharmaceutical composition. The foods especially include health functional foods. The “health functional food” defined in the present invention refers to food produced and processed using raw materials or ingredients with functionality, which are useful for the human body, and the “functionality” means intake for adjusting nutrients for the structures and functions of the human body or obtaining a useful effect on health applications such as physiological actions. The health functional food may have any one form of tablets, capsules, powders, granules, liquids, and pills.
In addition, the food composition of the present invention may be a food composition in which functional ingredients are added to various foods or beverages. The food may have any one form of, for example, beverages, powdered beverages, solids, chewing gum, tea, vitamin complexes, and food additives.
Further, the present invention provides an in vitro composition for promoting neurogenesis including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
The in vitro composition for promoting neurogenesis of the present invention may be used for experimental purposes and may be a composition for treating isolated cells or tissues requiring neuroregeneration by nerve damage. The in vitro composition for promoting neurogenesis of the present invention may be a medium composition containing the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate, and the medium may include, without limitation, any medium known to those skilled in the art, such as a medium containing serum (e.g., fetal bovine serum, horse serum, and human serum). Media that may be used in the present invention may include, for example, RPMI series, EMEM, MEM, Iscove's MEM, 199 medium, CMRL 1066, RPMI 1640, F12, F10, DMEM, a mixture of DMEM and F12, Way-mo, McCoy's 5A, or media known in the art suitable for culturing cells requiring neurogenesis. The neuroregeneration may be used for inducing neurogenesis, inducing neural differentiation, or inducing neural circuit restoration.
Further, the present invention provides a method for producing a composition for promoting neurogenesis including extracellular vesicles derived from three-dimensional spheroid-type cell aggregate produced by (a) preparing three-dimensional spheroid-type cell aggregate by 3-dimensionally (3D) culturing stem cells in a microwell with a diameter of 200 to 800 μm and a depth of 100 to 1000 μm: and (b) isolating extracellular vesicles from the three-dimensional spheroid-type cell aggregate.
According to the producing method, the extracellular vesicles derived from the three-dimensional spheroid-type cell aggregate, which have an excellent neurogenesis promoting effect, may be quickly mass-produced in accordance with GMP standards. Duplicated contents are omitted in consideration of the complexity of the present specification, and terms not defined otherwise in the present specification have the meanings commonly used in the art to which the present invention pertains.
Hereinafter, the present invention will be described in detail by Examples. However, the following Examples are just illustrative of the present invention, and the contents of the present invention are not limited to the following Examples.
Cells and extracellular vesicles were dissolved in a radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% triton X-100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and protease inhibitor). A total of 20 μg of proteins was isolated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Thereafter, the nitrocellulose membrane was cultured overnight at 4° C. together with a primary antibody against histone H2A.Z, histone H3, lamin A/C, flotillin-1 (1:1,000, Cell signaling technology, Beverly, MA, USA) or calreticulin (1:1,000, ThermoFisher Scientific, Inc., Rockford, IL, USA). After washed with Tris-buffered saline-Tween 20, the nitrocellulose membrane was cultured for 2 hours together with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000, anti-rabbit, Cell Signaling Technology, Beverly, MA, USA). Proteins were detected using a chemiluminescent substrate from ThermoFisher Scientific, Inc. (Waltham, MA, USA). Labeled proteins were visualized via an X-ray film (Agfa, Mortsel, Belgium).
ELISA was performed with a commercial kit according to the manual of an individual manufacturer. The following ELISA kits were used: gentamicin (5111GEN, EuroProxima, Arnhem, Nederland), bovine albumin (8100, Alpha Diagnostic, San Antonio, TX, USA), Hsp70 (Abcam, Cambridge, UK), CD63, CD9 and CD81 (System Biosciences, Palo Alto, CA, USA), histone H2A.Z. (Mybiosource, San Diego, CA, USA), calreticulin (Mybiosource) and cytochrome C (ThermoFisher Scientific, Inc.). All the kits included standard proteins. Therefore, the amounts of proteins and extracellular vesicles were determined based on a standard curve of each kit.
RNA was extracted from EVs using Trizol™ according to the instructions of the manufacturer and RNA was quantified by a nanodrop. RNA was made into cDNA through a reverse transcription (RT) process, and real-time PCR was performed according to the manual of the manufacturer using Taqman probes suitable for each miRNA and mRNA.
Purified EVs were stained with CFSE (5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl Ester) labeling dye (c-1157, Invitrogen) according to the manufacturer's instructions. Excess dye was removed by ultracentrifugation at 100.000 g for 1 hour. A human NSC cell line (ReNcells®) was treated with the labeled EVs (0.4 μg/ml) and cultured for 24 hours. After treatment, cells were washed twice with PBS and stained using a conventional immunocytochemistry protocol. The cells were incubated overnight at 4° C. with a mouse anti-SMA (1:100, Sigma aldrich) antibody. Thereafter, the cells were washed with PBS and cultured with a secondary antibody, DyLight-labeled anti-mouse IgG (1:200, 594 nm, Abcam) antibody. The cells were nuclear-stained using Vectashield™ with 1.5 μg/mL 4′-6′ diamidino-2-phenylindole (DAPI) (Vector Laboratories), and then the cells were imaged using a confocal microscope (LSM 700, Carl Zeiss, Germany).
Wharton's Jelly-derived mesenchymal stem cells (hereinafter referred to as WJ-MSC, Samsung medical center, Seoul, Korea) at passage 5 stage were received and cultured in a 37° C., 5% CO2 incubator. A growth medium was used with an α-modified eagle's medium (α-MEM, GIBCO, NY, USA) containing 10% fetal bovine serum (FBS) (GIBCO, NY, USA) and 50 μg/mL gentamicin (GIBCO, NY, USA). WJ-MSCs of passage 6 stage were used to prepare a 3D spheroidal cell aggregate.
The WJ-MSCs of passage 6 stage prepared in Example 1.1 were washed with PBS, treated with trypsin (TrypLE™ Express, GIBCO, NY, USA) and reacted in a CO2 incubator for 5 minutes. Thereafter, a new serum-free medium was added to neutralize trypsin and the cells were recovered to obtain a cell pellet using a centrifuge. Then, a new serum-free medium was added to prepare a cell suspension, and the cells were counted. After cell counting, 60 ml of the cell suspension was uniformly dispensed in a microarray including 69,000 microwells coated with 2-methacryloyloxyethyl phosphorylcholine polymer (MPC) with a diameter and depth of 500 μm×200 μm, respectively, to be a density of 400 cells/well, and maintained in a static state to induce the spontaneous formation of spheroidal cell aggregates, and cultured in a CO2 incubator at 37° C. for a total of 4 days to prepare a 3D spheroidal cell aggregate culture medium (hereinafter, referred to as a 3D-static-spheroid culture medium).
The 3D-static-spheroid culture medium prepared in Example 1.2 was collected, centrifuged at 2,500 g for 10 minutes, and filtered with a 0.22 μm syringe filter to remove cell debris. Thereafter, the 3D-static-spheroid culture medium passed through 300 kDa of a hollow fiber membrane (Pall, NY, USA) using a tangential flow filtration (TFF) system to remove proteins, and extracellular vesicles were first isolated and purified once more with physiological saline to obtain high-purity 3D-static-spheroid-derived extracellular vesicles (hereinafter, 3D-static-spheroid EVs) of the present invention.
The processes of Examples 1.1 to 1.3 were schematically illustrated in
The characteristics of the 3D-spheroidal cell aggregate (hereinafter, referred to as 3D-static-spheroid) present in the 3D-static-spheroid culture medium prepared in Example 1.2 were analyzed. As an experimental group, the 3D-static-spheroid culture medium prepared in Example 1.2 was used, and as a control group, a 3D mesenchymal stem cell spheroidal cell aggregate (hereinafter referred to as 3D-dynamic-PEG spheroid) culture medium prepared by culturing mesenchymal stem cells for 5 days was used according to a dynamic 3D cell culture method disclosed in
Registered Patent (Application No. 10-2016-0053026, method for producing stem cell-derived extracellular vesicles). With an optical microscope, microwells containing each culture medium were observed, which were illustrated in
As illustrated in
The size distributions of the 3D-static-spheroid prepared in Example 1.2 and the 3D-dynamic-PEG spheroid prepared in Example 2 were measured, and based on the measured size distribution data, dispersion coefficient, skewness and kurtosis were analyzed.
The skewness is a parameter capable of determining the inclined direction and degree of the distribution from the trend of a median value, and indicates a distribution with a longer tail to the right as closer to 1, and indicates a distribution with a longer tail to the left as closer to −1. In the case of a normal distribution, the skewness is 0.
The kurtosis is a parameter that indicates the degree of sharpness of the data distribution, and if the value is positive, it means that a relatively large number of data points are accumulated in the central part, and if the value is negative, it means that relatively few data are accumulated in the central part. In the case of a normal distribution, the kurtosis is 0.
The measured size distribution data was illustrated in
As illustrated in
As a result of comparing the size distributions of the 3D-static-spheroids and the 3D-dynamic-PEG spheroids, it was confirmed that the kurtosis value of the size distribution of the 3D-static-spheroids was relatively large, and the size distribution of the 3D-static-spheroids of the present invention showed a tendency to be concentrated in the median values. From these results, it was confirmed that when the 3D spheroids were produced by the method for producing the 3D-static-spheroids of the present invention, it was possible to produce 3D spheroids having a relatively constant size.
In order to observe the morphology of the 3D-static-spheroid EVs isolated in Example 1.3, the morphology was photographed using a transmission electron microscopy (TEM). Specifically, the 3D-static-spheroid EVs were fixed with 1% OsO4 dissolved in a 0.1 M phosphate buffer (PB) for 2 hours. The EM grids were adsorbed onto the droplets of extracellular vesicles with a formvar side facing downward for 1 minute. Thereafter, the EM grids were blotted with filter paper and reacted with 2% uranyl acetate for 15 seconds. Excessive uranyl acetate was removed, and the EM grids were observed using a TEM (JEM-1011, JEOL, Japan), and the observed image was illustrated in
As illustrated in
In order to confirm the concentration and size distribution of 3D-static-spheroid EVs isolated in Example 1.3, nanoparticle tracking analysis (NTA) was performed using NanoSight NS300 (Malvern, Worcestershire, UK). For optimal analysis, the 3D-static-spheroid EVs were pre-diluted in a vesicle-free phosphate buffer (PBS). The average size and concentration (particle/mL) were calculated by integrating three records, and the results were illustrated in
As illustrated in
Experiments were performed to confirm expression markers of 3D-static-spheroid EVs isolated in Example 1.3. A cell lysate and a secretome were used as a control. The cell lysate was prepared by a method of washing 3D-static-spheroids with PBS, treating the 3D-static-spheroids with trypsin, recovering cells, and obtaining a cell pellet using a centrifuge of the recovered cells. The secretome was prepared by a method of obtaining the cell pellet, isolating EVs from a supernatant of the culture medium through the process of Example 1.3, and obtaining the remaining culture secretome. For marker analysis, extracellular vesicles-specific positive markers CD9, CD63, CD81 and HSP70 were quantified using ELISA, and specific contaminant protein markers such as calreticulin, histone H2A.Z, cytochrome C, albumin, and antibiotics were quantified. In addition, histone H2A.Z, histone H3, lamin A/C, and calreticulin, which were specific contaminant protein markers of extracellular vesicles, were quantified using Western blot, and a positive marker of extracellular vesicles, flotillin-1 was quantified. The ELISA analysis result and the Western blot result were shown in
As illustrated in
The experiment was performed to compare the productions of the 3D-static-spheroid EVs, which were the extracellular vesicles produced by the production method of Example 1, extracellular vesicles (3D-dynamic-PEG spheroid EVs) isolated from the 3D-dynamic-PEG spheroids of Example 2, and extracellular vesicles (2D-EVs) isolated from stem cells cultured by a conventional 2D culture method. The 2D-EVs were prepared by the following process. The stem cells cultured for 3 days in a cell stack were washed with PBS, replaced with a serum-free medium, and further cultured for 2 days. The culture medium was recovered and the cell debris was continuously removed using centrifugation and a 0.2 um filter. Thereafter, the culture medium passed through a hollow fiber membrane using a TFF system to remove proteins, and the EVs were first isolated, and purified once more with physiological saline to obtain high-purity 2D-EVs. The productions per cell derived from the prepared 3D-static-spheroid EVs, 3D-dynamic-PEG spheroid EVs, and 2D-EVs were compared and illustrated in Table 2 and
Sequencing analysis was performed to analyze miRNA components contained in 3D-static-spheroid EVs, which were extracellular vesicles prepared by the preparation method in Example 1, and the analysis result of miRNA components contained in the 3D-static-spheroid EVs was illustrated in
As illustrated in
Changes in miRNA expression were profiled using a small RNA sequencing method. Based on the results of the profiling study, miRNAs with significant changes in EVs secreted from stem cells cultured using a 3D culture method were verified compared to 2D-EVs cultured using existing culture methods, and the results were illustrated in
As illustrated in
Stem cell therapy was known to have a problem of donor variation in which components varied depending on a donor. An experiment was performed to confirm whether the 3D-static spheroid EVs of the present invention exhibited a more consistent miRNA profile without a donor variation issue. Samples from each donor were received from the Samsung medical center (Seoul, Korea) and used. The numbers of EVs, EV protein amounts, and miRNA profiles produced by each donor were compared with each other in 2D-cultured WJ-MSCs and 3D-cultured WJ-MSCs of Example 1.1 and 3D-static-spheroid EVs, which were the extracellular vesicles produced by the production method of Example 1. miRNA was profiled by a Small RNA sequencing method, and the results were shown in
As illustrated in
As illustrated in
These results indicated that the 3D-static-spheroid EVs may reduce a difference in therapeutic active ingredients according to a donor and exhibit better therapeutic effects.
To further confirm the usefulness of 3D-static-spheroid EVs in promoting neurogenesis, target cells, neural stem cells pNSCs were treated with the 3D-static-spheroid EVs for 6 hours, and then the expression level of neurogenesis-related mRNA was confirmed in neural stem cells through qPCR.
As illustrated in
As a result of combining all of the results, in the 3D-static-spheroid EVs of the present invention, compared to WJ-2D-EVs or 3D-dynamic-spheroid EVs, miR-27a, miR-132, miR-146a and miR-146b which were miRNAs related to neurogenesis, were significantly increased, and VEGF, BDNF, FGF, and NGF mRNA were more contained. Accordingly, it was confirmed that it may be expected to exhibit a better effect on neurogenesis as compared to previously reported EVs.
To evaluate the cell incorporation ability of 3D-static-spheroid EVs, CFSE-labeled 3D-static-spheroid EVs were treated to a human NSC cell line (ReNcells®). The cells were incubated for 24 hours, and confirmed by confocal microscopy (LSM 700, Carl Zeiss, Germany), and at 12 hours, the expression of miR-27a-3p in ReNcells® was confirmed by qPCR, and the results were illustrated in
As illustrated in
Through this, it was confirmed that when the target neural cells were treated with the 3D-static-spheroid EVs, a neurogenesis-promoting substance highly expressed in the 3D-static-spheroid EVs, such as miR-27a-3p, was effectively delivered to the cells. This result indicates that the 3D-static-spheroid EVs may be used as a therapeutic agent for neurogenesis.
To investigate the neuronal differentiation ability of 2D-cultured stem cell-derived extracellular vesicles (2D-EVs) and 3D-static-spheroid EVs, neural stem cells (NSCs) primarily cultured from the cerebral cortex isolated from SD rat embryos on day 14.5 were treated with 2D-EVs and 3D-static-spheroid EVs at 5×108/ml each, and then the neuronal differentiation ability was compared with a control group containing only a basic medium or a nerve growth factor (NGF)-treated group. The neuronal differentiation ability according to treatment with 2D-EV, 3D-static-spheroid EV, NGF, and the basic medium was confirmed by measuring the lengths of neurites under a microscope on day 4 of culture, and the results were illustrated in
As illustrated in
To prepare a stroke animal model, a photothrombotic (PT) cerebral infarction model was prepared. PT stroke was induced in the right hand sensorimotor cortex of a mouse using adult male C57BL/6J mice (Orient Bio Inc., Seongnam, South Korea) of 20 to 25 g (8 to 12-week-old). Briefly, mice were anesthetized by intraperitoneal administration of a mixture of ketamine (100 mg/kg, Yuhan Corporation, Seoul, Korea) and xylazine (10 mg/kg, Rompun® inj., Bayer, Berlin, Germany) and placed in a stereotaxic apparatus (KOPF Instruments, Tujunga, CA, USA). Using a scalpel, a midline incision was performed along the scalp from the eyes to the neck, and the skull was exposed after removing the periosteum. A Rose Bengal solution (30 mg/kg, saline 10 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was administered intravenously through the jugular vein, and after 5 minutes, a 100 mW, 532 nm diode-pumped solid-state green laser (Dongwoo Optron Co., Ltd., Gwangju) provided with a 3 mm-diameter illumination was positioned at 2.5 mm lateral to bregma. The laser was activated for 15 minutes in a region of interest (ROI) and the incision site was sutured using 6-0 monofilament suture. During surgery, rats were maintained at a body temperature of 37.0 to 37.5° C.
The photothrombotic cerebral infarction model mouse prepared in Example 11.1 was administered with the 3D-Static-Spheroid EVs, and then to examine morphological changes using MRI, infarct lesion volume and ventricular volume were measured using a T2-weighted image (T2WI). Specifically, 3D-static-spheroid EV (6×108 EV/mouse) was injected into the blood vessels of the mouse in the photothrombotic cerebral infarction model, and after 3 days (PBS group, n=20; EV group, n=23), 14 days (PBS group, n=8; EV group, n=10), and 28 days (PBS group, n=8; EV group, n =6), MRI T2-weighted images (T2WI) were taken to compare changes in cerebral infarction lesions and ventricular volumes in the experimental and control groups. The results were illustrated in Table 3 and
†p value = 0.052
As can be seen in Table 3 and
Transient middle cerebral artery occlusion (tMCAo) was induced using an intraluminal occlusion method. 8-week-old male Sprague-Dawley rats (270 to 300 g) were anesthetized with 1.5% isoflurane during surgery, and a heating pad was used to maintain the body temperature of the rats between 37 and 37.5° C. during the surgery and occlusion period. A round-ended 4-0 surgical monofilament nylon suture was moved from the left common carotid artery into the lumen of the internal carotid artery until the origin of the middle cerebral artery was occluded. Reperfusion was performed after tMCAo 90 minutes.
To confirm a neurogenesis effect, after intravenous injection of 3 doses (0.3×1010/rat, 1.5×1010/rat, and 3.0×1010/rat) of 3D-static-spheroid EVs into the ischemic stroke animal prepared in Example 11.3, after two weeks of stroke, immunofluorescence staining was performed using a positive neuron marker DCX and a cell proliferation marker Ki67, as an indicator of observing neurogenesis in brain tissue. The immunofluorescence staining result and quantified Ki67/DCX result of each dose experimental group were shown in
As illustrated in
3D-static-spheroid EVs (6×108 EV/mouse) were injected into the blood vessels of mice in the photothrombotic cerebral infarction model prepared in Example 11.1, and changes in brain microstructure/connectivity were examined using diffusion-tensor imaging (DTI). In the photothrombotic cerebral infarction model, the 3D-static-spheroid EVs (6×108 EV/mouse) were injected into the blood vessels of the mouse, and after 3 days (PBS group, n=20; EV group, n=23), 14 days (PBS group, n=8; EV group, n=10), and 28 days (PBS group, n=8; EV group, n=6), MRI diffusion tensor imaging (DTI) and fiber tractography images were taken, and the treatment effect was demonstrated at 14 and 28 days after stroke using relative changes in fractional anisotropy (FA) and fiber density (FD) values from external capsule (EC) and internal capsule (IC) regions of interest (ROIs). The results of DTI and fiber tractography were illustrated in
As illustrated in Table 4 and
After injecting 3D-static-spheroid EVs (6×108 EV/mouse) into the blood vessels of the mouse, changes in neural circuit were examined using diffusion tensor tractography (DTT) images. After 14 days (PBS group, n=8: EV group, n=10) and 28 days (PBS group, n=8: EV group, n=6), MRI diffusion tensor tractography (DTT) images were taken and the result of comparing the change degrees in the neural circuits of the treated group and the control group was illustrated in
As illustrated in
To examine the enhancement of neural circuit by extracellular vesicles, resting state functional MRI was performed after 28 days of stroke induction in the cerebral infarction animal model prepared in Example 11.1. Analysis of resting state functional connectivity differences between the control group and the 3D-static-spheroid EV group was performed on 16 regions of interest. Six cortical regions and two cortical regions were selected from the ipsilesional and contralesional sides for analysis. The analysis results were illustrated in
As illustrated in
It was confirmed through the previous Example that when the 3D-static spheroid EVs of the present invention were injected into the cerebral infarction animal model prepared in Example 11.1, the neural circuit generation was effectively induced. To determine whether the loss of motor function caused by neurogenesis in the cerebral infarction animal model was recovered, a forelimb asymmetry test (cylinder test) and a foot defect test (grid walking test) were performed. More specifically, 3D-static-spheroid EVs (6×108 EV/mouse) were injected into the blood vessels of the mouse in the prepared photothrombotic cerebral infarction model, and at 14 days (PBS group, n=8: 3D-static-spheroid EV treatment group, n=10), and 28 days (PBS group, n=8: 3D-static-spheroid EV treatment group, n=6), the analysis was performed, and the results were illustrated in
As illustrated in
In addition, in order to confirm the correlation between functional restoration and MRI, correlation analysis was performed between two behavioral tests (cylinder test and grid walking test) and rs-fMRI results, and the results were illustrated in
As illustrated in
Through Examples above, the excellent effect of the 3D-static-spheroid EVs of the present invention was confirmed. The preparation method of Example 1 was performed in the same manner, but to confirm whether the same effect was observed even in EVs prepared under different microwell specifications and cell number conditions, the cells were incubated by changing the cell count specification per microwell from 400 cells/well to 200 cells/well, or changing the microwell specification from 500 μm×200 μm in diameter and depth to 500 μm×600 μm, or a flat well with a diameter of 800 μm and no depth.
The experimental conditions changed from the preparation method of Example 1 were shown in Table 5 below.
The WJ-MSCs of passage 6 stage prepared in Example 1.1 were washed with PBS, treated with trypsin (TrypLETM Express, GIBCO, NY, USA) and reacted in a CO2 incubator for 5 minutes. Thereafter, a new serum-free medium was added to neutralize trypsin and the cells were recovered to obtain a cell pellet using a centrifuge. Then, a new serum-free medium was added to prepare a cell suspension, and the cells were counted. After counting the cells, the cells were uniformly dispensed into microwells under the conditions shown in Table 5 above, maintained in a static state to induce spontaneous spheroidal cell aggregate formation, and incubated in a CO2 incubator at 37° C. for a total of 4 days to prepare a 3D spheroidal cell aggregate culture medium.
It was confirmed that spheroids were formed uniformly in the same manner as in Example 1 under the conditions of Experimental Examples 1 to 3, and the 3D spheroidal cell aggregate culture medium was recovered to obtain spheroid-derived extracellular vesicles by the method of Example 1.3. The size distribution of the obtained extracellular vesicles was measured, and the roundness and solidity of the spheroids were additionally confirmed, and the results were illustrated in
As illustrated in
Experimental Examples 1 to 3 also had the Roundness values of 0.8751, 0.8669, and 0.8601, respectively. In addition, it was confirmed that similarly to the average Solidity value of 0.9488 (CV 2.64%) of the 3D spheroidal cell aggregate of Example 1, the spheroidal cell aggregates of Experimental Examples 1 to 3 also had the average Solidity values of 0.9744, 1, and 0.9752, respectively.
These results showed that even if the number of cells per microwell was changed to 200 or 400 and the diameter of the microwell was changed to 400 to 800, the 3D spheroidal cell aggregate with a similar shape may be effectively formed through the method of Example 1.
Since it was confirmed that spheroidal cell aggregates having a similar shape to Example 1 could be prepared even under the conditions of Experimental Examples 1 to 3, additionally, extracellular vesicles were isolated and obtained from the spheroidal cell aggregates by the method of Example 1.3, and it was confirmed whether the isolated and obtained EVs also showed the same miRNA expression patterns. Comparison of the miRNA expression patterns was confirmed using extracellular vesicles derived from spheroidal cell aggregates prepared by the methods of Experimental Examples 1 and 2 under different microwell conditions. Analysis of expressed miRNA was confirmed through the same qPCR method as in Example 8. The results were illustrated in
As illustrated in
In summary, the 3D-static spheroid EVs of the present invention had high expression of neurogenesis-related miRNAs and neurogenesis factors, and had excellent neurogenesis ability in vitro and in vivo, neural circuit generation in vitro and in vivo, and the stroke improvement effect, and thus is expected to exhibit an excellent effect in preventing or treating various diseases that require neural damage and neurogenesis.
As described above, specific parts of the present invention have been described in detail, and it will be apparent to those skilled in the art that these specific techniques are merely preferred embodiments, and the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2021-0058171 | May 2021 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2022/006429 | 5/4/2022 | WO |
